Literature DB >> 22139972

Implications of a positive crossmatch in liver transplantation: a 20-year review.

Richard Ruiz1, Koji Tomiyama, Jeffrey Campsen, Robert M Goldstein, Marlon F Levy, Greg J McKenna, Nicholas Onaca, Brian Susskind, Glenn W Tillery, Goran B Klintmalm.   

Abstract

Whether a positive crossmatch result has any relevance to liver transplantation (LT) outcomes remains controversial. We assessed the impact of a positive crossmatch result on patient and graft survival and posttransplant complications. During a 20-year period, 2723 LT procedures with crossmatch results were identified: 2479 primary transplants and 244 retransplants. The rates of positive B cell and T cell crossmatches were 10.1% and 7.4%, respectively, for primary transplants and 14.6% and 6.4%, respectively, for retransplants (P = 0.049 for a B cell crossmatch). Across all primary transplants, females (P < 0.001) and patients with autoimmune hepatitis (P < 0.001) had greater frequencies of positive crossmatches. There was no effect from race or age. For both primary transplants and retransplants, patient survival and graft survival were not affected by the presence of a positive crossmatch. With respect to posttransplant complications, there were no differences in rejection episodes (hyperacute, acute, or chronic) or technical complications (biliary and vascular) between negative and positive crossmatch groups. However, there were significant differences in the pathological findings of preservation injury (PI) on liver biopsy samples taken at the time of transplantation and within the first week of transplantation (P = 0.003 for B cells and P = 0.03 for T cells). In summary, a positive crossmatch had no significant impact on patient survival or graft outcomes. However, there was a significantly higher incidence of PI in primary LT recipients with a positive crossmatch. This finding is important for a broader understanding of PI, which may include a significant immunological component.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22139972     DOI: 10.1002/lt.22474

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  6 in total

Review 1.  What's new in clinical solid organ transplantation by 2013.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2014-12-24

Review 2.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

Review 3.  Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.

Authors:  Arno Kornberg
Journal:  World J Hepatol       Date:  2015-06-18

4.  De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.

Authors:  H Kaneku; J G O'Leary; N Banuelos; L W Jennings; B M Susskind; G B Klintmalm; P I Terasaki
Journal:  Am J Transplant       Date:  2013-06       Impact factor: 8.086

5.  The impact of alloantibodies directed against the second donor on long-term outcomes of repeat liver transplantation.

Authors:  Qingyong Xu; Brad Shrum; Steve Leckie; Anton Skaro; Vivian C McAlister
Journal:  Hepatobiliary Surg Nutr       Date:  2019-06       Impact factor: 7.293

6.  De Novo Donor Specific Antibody and Long-Term Outcome After Liver Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Zahra Beyzaei; Bita Geramizadeh; Zahra Bagheri; Sara Karimzadeh; Alireza Shojazadeh
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.